Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Kristin Busse PharmD

Kristin Busse PharmD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: School of Pharmacy Administration
Division: Administration
Program: Administration

View Curriculum Vitae

Publications (16)

  • Inpefa (sotagliflozin). (Pape Z, El-Alfy AT, Busse K) WMJ 2024;123:P1-P2 PMID: 38578622 SCOPUS ID: 2-s2.0-85190074508 04/05/2024    
  • Research During COVID-19: Reflections From an Institutional Review Board Office. (Busse K, Griffin S, Spellecy R) WMJ 2023 Dec;122(5):434-436 PMID: 38180941 SCOPUS ID: 2-s2.0-85181847738 01/05/2024    
  • Cannabidiol. (Thao KC, El-Alfy AT, Busse K) WMJ 2023;122:P2 PMID: 37656127 SCOPUS ID: 2-s2.0-85169371161 09/01/2023    
  • Auvelity (dextromethorphan/bupropion). (Abuzoor A, El-Alfy AT, Busse K) WMJ 2023;122:P4 PMID: 36724488 SCOPUS ID: 2-s2.0-85147235774 02/02/2023    
  • Paxlovid (nirmatrelvir/ritonavir). (Busse K, El-Alfy AT) WMJ 2022;121:P3 PMID: 36395430 SCOPUS ID: 2-s2.0-85142209002 11/18/2022    
  • Fluvoxamine and COVID-19. (El-Alfy AT, Busse K) WMJ 2022;121:P2 PMID: 35671339 SCOPUS ID: 2-s2.0-85131500119 06/08/2022    
  • Aducanumab. (Busse K, El-Alfy AT) WMJ 2022;121:P1 PMID: 35381124 SCOPUS ID: 2-s2.0-85127697153 04/06/2022    
  • Collective Action: The Medical College of Wisconsin COVID-19 Vaccination Program. (Sanchez AM, Busse K, MacKinnon K, Henk L, MacKinnon GE, Brown J, Mauermann S, Dobrowski T, Jungmann J, Bultman J, Singh S, Nattinger AB) WMJ 2021 Dec;120(4):305-308 PMID: 35025179 SCOPUS ID: 2-s2.0-85123461368 01/14/2022       4 Citations
  • The History of Human Subjects Research and Rationale for Institutional Review Board Oversight. (Spellecy R, Busse K) Nutr Clin Pract 2021 Jun;36(3):560-567 PMID: 33438782 SCOPUS ID: 2-s2.0-85099392572 01/14/2021       14 Citations
  • Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. (Busse KH, Hadigan C, Chairez C, Alfaro RM, Formentini E, Kovacs JA, Penzak SR) J Acquir Immune Defic Syndr 2009 Oct 01;52(2):235-9 PMID: 19648824 PMCID: PMC2815103 SCOPUS ID: 2-s2.0-70349680871 08/04/2009       22 Citations
  • Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. (Ramanathan R, Pau AK, Busse KH, Zemskova M, Nieman L, Kwan R, Hammer JH, Mican JM, Maldarelli F) Clin Infect Dis 2008 Dec 15;47(12):e97-9 PMID: 18991509 PMCID: PMC2941349 SCOPUS ID: 2-s2.0-56749153964 11/11/2008       37 Citations
  • Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. (Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR) J Acquir Immune Defic Syndr 2008 Aug 15;48(5):561-6 PMID: 18645517 PMCID: PMC2669927 SCOPUS ID: 2-s2.0-50949099671 07/23/2008       22 Citations
  • Pharmacological enhancement of protease inhibitors with ritonavir: an update. (Busse KH, Penzak SR) Expert Rev Clin Pharmacol 2008 Jul;1(4):533-45 PMID: 24410555 SCOPUS ID: 2-s2.0-49549104496 07/01/2008       11 Citations
  • Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. (Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey RT Jr) J Clin Pharmacol 2008 Jun;48(6):671-80 PMID: 18420532 PMCID: PMC2658757 SCOPUS ID: 2-s2.0-44049088374 04/19/2008       30 Citations
  • Part XIII. Systemic antifungal therapy. (Busse KH, Gentry CA, Bronze MS, Greenfield RA) J Okla State Med Assoc 2007 Sep;100(9):344-51 PMID: 18020039 SCOPUS ID: 2-s2.0-38449120499 11/21/2007    
  • Darunavir: a second-generation protease inhibitor. (Busse KH, Penzak SR) Am J Health Syst Pharm 2007 Aug 01;64(15):1593-602 PMID: 17646561 SCOPUS ID: 2-s2.0-34547421880 07/25/2007       20 Citations
    • Last update: 04/24/2024